Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Moradec’s secondary ADCs empower rapid, economical pre-screening of antibody leads for ADC development, showing specific cytotoxic effects in vitro when combined with appropriate primary antibodies against cancer cell-surface receptors. Moradec is a niche provider of antibody-drug conjugate discovery tools and services, specializing in secondary ADC reagents and phage display human antibody libraries; its enabling technologies are widely used in preclinical oncology and biotherapeutic research, but it does not develop its own therapeutics or pursue clinical drug development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Moradec.